Evommune, Inc.
EVMN
$18.41
-$1.82-9.00%
NYSE
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Net Income | 50.46% | -422.88% | |||
| Total Depreciation and Amortization | 15.38% | 39.11% | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | -14,004.84% | 251.55% | |||
| Change in Net Operating Assets | -123.11% | -362.11% | |||
| Cash from Operations | -203.83% | -394.80% | |||
| Capital Expenditure | -- | -- | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | 79.19% | 38.92% | |||
| Cash from Investing | 79.52% | 39.93% | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -43.52% | -148.39% | |||
| Issuance of Common Stock | -- | 0.00% | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -- | -- | |||
| Cash from Financing | 59,675.00% | -153.33% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 4,241.30% | -321.75% | |||